GNLX - GENELUX Corp
IEX Last Trade
2.445
0.045 1.840%
Share volume: 360
Last Updated: Thu 26 Dec 2024 08:25:49 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$2.40
0.05
1.88%
Fundamental analysis
23%
Profitability
25%
Dept financing
9%
Liquidity
60%
Performance
15%
Performance
5 Days
3.91%
1 Month
-4.02%
3 Months
13.27%
6 Months
11.16%
1 Year
-84.09%
2 Year
-61.14%
Key data
Stock price
$2.44
DAY RANGE
$2.40 - $2.49
52 WEEK RANGE
$1.77 - $16.36
52 WEEK CHANGE
-$85.24
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Thomas Zindrick
Region: US
Website: www.genelux.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: www.genelux.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our principal executive offices are located at 2625 Townsgate Road, Suite 230, Westlake Village, California.
Recent news